Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD) Biosimilar business growing 21% in constant currencies All regions contributing to growth Acquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on May 31, 2025 or earlier under certain circumstances Jubbonti® and Wyost® are first and only FDA-approved biosimilars to and interchangeable with Prolia*® and [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and quality Sandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolio [...]
EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m2 means Kundl can now manufacture 240 million packages per year Represents capacity increase of 20% over 2023 and more than doubling from 2021 output levels Automation and innovative technologies allow production [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in USD) Full-year 2023 net sales of USD 9.6 billion, up 7% in constant currencies (up 6% in USD) Strong growth across all three regions and double-digit [...]
Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®* (denosumab) FDA approval based on robust clinical studies and totality of evidence, which show no clinically meaningful differences from reference medicines Basel, March 5, 2024 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting Remco Steenbergen appointed as Sandoz CFO and member of Executive Committee as of July 1, 2024, and consequently not standing for [...]
CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for providers and patients Basel, March 4, 2024 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI®* [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Sandoz US to pay USD 265 million in exchange for full release of all claims by the class Resolves all federal antitrust damages for direct purchaser class plaintiffs’ claims in this litigation, if approved by Court Basel, February 29, 2024 – Sandoz [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual General Meeting François-Xavier Roger announced to pursue a new executive responsibility and therefore to step down from the Sandoz Board of Directors post publication [...]